JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025. Barclays 27 th Annual Global Healthcare... Read More

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share 1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve... Read More

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing... Read More

JUPITER, Fla. / Feb 13, 2025 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and... Read More

JUPITER, Fla. / Feb 06, 2025 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 at 2:40 p.m. Eastern Time. Ligand management is scheduled to host one-on-one meetings with investors and attendees during the... Read More

Introduces 2025 full year revenue guidance of $180 million to $200 million, a 17% increase in revenue growth over 2024, and core adjusted earnings per diluted share of $6.00 to $6.25 Twelve commercial-stage programs and late-stage pipeline are expected to drive strong revenue growth over the next five years Long-term royalty receipts expected to deliver at least a 22% compound annual growth rate JUPITER, Fla. / Dec 10, 2024... Read More

JUPITER, Fla. / Nov 14, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 12:40 p.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees during the conference.... Read More

Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share 1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today JUPITER,... Read More

JUPITER, Fla. / Nov 01, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time. The in-person event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial... Read More

JUPITER, Fla. / Oct 23, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast... Read More

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active... Read More

JUPITER, Fla. / Aug 20, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26 th Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time. Management is scheduled to host one-on-one meetings with investors and attendees... Read More

Conference call at 4:30 p.m. Eastern Time today JUPITER, Fla. / Aug 06, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.... Read More

JUPITER, Fla. / Jul 23, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information... Read More

Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023 Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to... Read More

FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre JUPITER, Fla. / Jun 27, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration (FDA) for Ohtuvayre™ (ensifentrine).... Read More

CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE JUPITER, Fla. / Jun 18, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug Administration... Read More

JUPITER, Fla. / May 23, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming investor conferences: Craig-Hallum Institutional Investor Conference (Minneapolis). Management will participate in one-on-one meetings on May 29, 2024. Goldman Sachs Global Healthcare... Read More

Conference Call Begins at 4:30 p.m. Eastern Time Today JUPITER, Fla. / May 07, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. “We... Read More

Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activities Ligand entitled to royalties and milestone payments on six Agenus-partnered programs as well as royalties on future global net sales generated by BOT/BAL Transaction allows for a syndication of up to an additional $125 million in capital JUPITER, Fla. and LEXINGTON, Mass. /... Read More

JUPITER, Fla. / Apr 23, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date:... Read More

Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis LONDON / Apr 08, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of... Read More

Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 JUPITER, Fla. & DURHAM, N.C. / Apr 03, 2024 / Business Wire / Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the... Read More

SAN DIEGO / Mar 05, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26 th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time. Management will participate in one-on-one investor meetings during the... Read More

SAN DIEGO / Mar 04, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024. The award was granted under Ligand’s 2022... Read More

Conference Call and Webcast at 8:30 a.m. Eastern Time Today SAN DIEGO / Feb 27, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this... Read More

Fycompa® is the 16 th Captisol-enabled™ product approved worldwide SAN DIEGO / Feb 22, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa ®... Read More

Expansion Deepens Ligand’s Commercial, Clinical and Investment Expertise SAN DIEGO / Feb 16, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments. Both executives will report to CEO Todd Davis. “Rich and Karen... Read More

SAN DIEGO / Feb 13, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and... Read More

SAN DIEGO / Feb 01, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective February 1, 2024, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units (“RSUs”) and 40,000 performance stock units (“PSUs”) (at the target level) to two non-executive employees.... Read More

ZELSUVMI™ is expected to be commercially available during the second half of 2024 SAN DIEGO / Jan 05, 2024 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. i The FDA... Read More

SAN DIEGO / Dec 12, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A... Read More

COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc ., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations examining clinical data tied to Sermonix’s E valuation of La sofox i fe n e in E SR1 Mutations (ELAINE) studies. The presentations were... Read More

SAN DIEGO / Dec 06, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members of Ligand’s senior management team will provide an update on the company’s strategy and portfolio as well as a multi-year financial outlook and a 2024 guidance preview. The in-person event will be held at the Harvard Club in New York City from 10:30am –... Read More

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with Microcystic Lymphatic Malformations U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ rapamycin for the Treatment of Microcystic Lymphatic Malformations in November 2023 WAYNE, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) --... Read More

COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held Dec. 5-9 at the Henry B. Gonzalez... Read More

Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today SAN DIEGO / Nov 08, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a... Read More

COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that a case report detailing a durable complete remission during its Phase 2 ELAINE-1 study was published in JCO Precision Oncology ( JCO PO ). The case marks the first-ever... Read More

TZIELD is the first and only FDA approved treatment to delay the onset of Stage 3 type 1 diabetes SAN DIEGO / Nov 01, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has acquired Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD (teplizumab-mzwv), that is owed a... Read More

SAN DIEGO / Oct 25, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date: Wednesday, November... Read More

More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual health was negatively impacted by prior endocrine therapy (61%) Findings were presented in a poster at The Menopause Society 2023 Annual Meeting COLUMBUS, Ohio,... Read More

SAN DIEGO / Sep 27, 2023 / Business Wire / Ligand Pharmaceuticals (NASDAQ: LGND) announced that it has closed the transaction to acquire assets o f Novan, Inc. (“Novan”) following the offer it made on July 17, 2023. On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing. In September 2023, the Bankruptcy Court... Read More

SAN DIEGO / Sep 26, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board. “We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and... Read More

SAN DIEGO / Sep 22, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been granted marketing authorization by the European Commission (EC) for Enrylaze ® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic... Read More

SAN DIEGO / Sep 21, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function... Read More

Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biology Ligand contributes $15 million in exchange for economic interest in select Primrose programs Ligand improves cash expense outlook and raises EPS guidance SAN DIEGO / Sep 18, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand,”... Read More

SAN DIEGO / Sep 01, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 50,000 shares of its common stock to one non-executive employee in connection with the employee’s commencement of employment under the... Read More

Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO / Aug 08, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.... Read More

SAN DIEGO / Jul 27, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals. If approved, V116 would be the first... Read More

SAN DIEGO / Jul 25, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’s CEO Todd Davis, President... Read More

Ligand provides bridge and debtor-in-possession ("DIP") financing to Novan SAN DIEGO / Jul 17, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier... Read More

One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast... Read More

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster presentation detailing the results of its ELAINE-2 clinical study with longer patient follow-up. The poster was initially presented yesterday at the 2023 American Society... Read More

COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today shared an abstract to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting detailing the results of its ELAINE-2 clinical study with longer... Read More

Study achieves primary endpoint, demonstrating statistically significant reductions in liver fat from baseline to week 12 in patients receiving VK2809 as compared to placebo Ligand is entitled to receive a $10 million milestone payment upon initiation of a Phase 3 clinical trial as well as royalties of 3.5% to 7.5% on commercial sales of VK2809, if approved SAN DIEGO / May 16, 2023 / Business Wire / Ligand Pharmaceuticals... Read More

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO / May 04, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this... Read More

SAN DIEGO / Apr 24, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’s CEO Todd Davis, President and... Read More

Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development Phase 3 study is supported by previously presented ELAINE-1 and ELAINE-2 Phase 2 study results Sermonix anticipates dosing the first patient in first half of 2023 COLUMBUS, Ohio and PALO ALTO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held... Read More

ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. , a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today announced that its lead drug candidate, lasofoxifene, improved vaginal/vulvar symptoms while fulvestrant worsened them in a study of postmenopausal women with locally... Read More

SAN DIEGO / Feb 17, 2023 / Business Wire / Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. This... Read More

COLUMBUS, Ohio, and SAN FRANCISCO , Feb. 16, 2023 /PRNewswire/ -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix's investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated in a new study arm of the ongoing I-SPY endocrine program sponsored by Quantum Leap. This portion of the study targets patients with newly diagnosed estrogen... Read More

Potential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, mostly children Berdazimer gel, 10.3% has the potential to be the first FDA-approved prescription product for molluscum Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc.... Read More